Triolo G, Canavese C, Di Giulio S
Servizio di Nefrologia e Dialisi, Ospedale V. Valletta, Torino, Italy.
Int J Artif Organs. 1998 Nov;21(11):751-6.
Guidelines for the treatment of anemia in chronic renal failure (CRF) patients were recently published by NKF-DOQI. The background was provided by the fact that anemia in CRF patients fulfills all the criteria requested for the outlining of guidelines. In fact: 1) anemia is a clinically relevant problem for CRF patients; 2) it may be prevented by adequate erythropoietin (EPO) therapy; 3) a great variability in its management exists, not only concerning the optimal hematocrit (HCT) level, but also the treatment schedule as well as iron supplementation. More than eight hundred forty five scientific articles were retrieved in full text, eventually leading to 530 structurally reviewed papers (349 cited in the final text) thus providing the basis for the strength of recommendations (evidence or opinions): all topics were subdivided into 7 main issues (diagnostic and therapeutic). Main results were the following: HCT, hemoglobin (Hb), red blood cell, serum iron binding capacity, percent transferrin saturation (TSAT) and serum ferritin (FERR), to evaluate the degree of anemia and iron status; HCT 33 to 36% and Hb 11 to 12 g/dl as possible target levels; TSAT >20% and FERR >100 ug/dl as acceptable lower values for iron status; oral iron administration not <200 mg/day of elemental iron and intravenous iron 50-100 mg/week or 500-100 mg/month (for patients on predialysis or peritoneal dialysis) as therapeutic schedules; subcutaneous route for EPO administration at 80-120 U/kg body weight/week as starting doses. Some issues may be debatable, such as, the underestimation of dialysis efficacy among the causes of inadequate response to EPO as well as the risk of thrombosis among the possible side effects of EPO therapy, or the lack of recommendation for upper limits of FERR values. However, this exhaustive study is an important demonstration of efforts to improve the quality of care in CRF patients.
美国国家肾脏基金会-透析和移植临床实践指南(NKF-DOQI)最近发布了慢性肾衰竭(CRF)患者贫血的治疗指南。CRF患者贫血符合制定指南所需的所有标准,这为指南提供了背景依据。事实上:1)贫血是CRF患者的一个临床相关问题;2)通过适当的促红细胞生成素(EPO)治疗可以预防贫血;3)贫血管理存在很大差异,不仅涉及最佳血细胞比容(HCT)水平,还包括治疗方案以及铁补充剂的使用。共检索到845多篇全文科学文章,最终形成530篇经过结构审查的论文(最终文本引用了349篇),从而为推荐强度(证据或观点)提供了依据:所有主题分为7个主要问题(诊断和治疗)。主要结果如下:通过HCT、血红蛋白(Hb)、红细胞、血清铁结合能力、转铁蛋白饱和度百分比(TSAT)和血清铁蛋白(FERR)来评估贫血程度和铁状态;将HCT 33%至36%和Hb 11至12 g/dl作为可能的目标水平;TSAT>20%和FERR>100 ug/dl作为铁状态可接受的较低值;治疗方案为口服铁剂元素铁不少于200 mg/天,静脉铁剂50 - 100 mg/周或500 - 100 mg/月(适用于透析前或腹膜透析患者);EPO皮下给药起始剂量为80 - 120 U/kg体重/周。有些问题可能存在争议,例如,在EPO反应不足的原因中对透析疗效的低估,以及EPO治疗可能的副作用中血栓形成的风险,或者对FERR值上限缺乏推荐。然而,这项详尽的研究是为提高CRF患者护理质量所做努力的一个重要证明。